Physiogenex

Physiogenex is a leading CRO providing non clinical services in metabolic disorders and complications.

[Physiogenex @physiogenex]

Don't miss Dr. François Briand at the Obesity Week 2019 in Las Vegas this week!

Poster session on November 5th, 12pm to 1:30pm: "Lorcaserin Has Less Metabolic Benefits Than Liraglutide in Free Choice Diet-Induced Obese Rats".

[email protected]

#obesityweeklasvegas

[Physiogenex @physiogenex]

Physiogenex’s website gets a new look! We have completely redesigned our website to provide our visitors with the best browsing experience.
Have a look at our expertise, team, technical sheets and more following this link: https://t.co/hlgfE0hiTx

[Physiogenex @physiogenex]

Today Dr. François Briand attends the 55th Annual Meeting of the EASD at Fira Barcelona Gran Via (Barcelona, Spain).
Poster presentation: "Liraglutide shows better weight-loss and cardiometabolic benefits than lorcaserin and pioglitazone in a novel diet-induced obese rat model".

[Physiogenex @physiogenex]

Physiogenex will attend the EASL NAFLD Summit 2019 on September 27. Dr. François Briand will present a poster during the ePoster session 1 starting at 7:15pm.

Poster: "Liraglutide improves NASH and metabolic disorders in a 3-week diet-induced NASH mouse model."

[Physiogenex @physiogenex]

Dr. François Briand will attend the 55th Annual Meeting of the EASD in Barcelona, Spain on September 17, 2019. He will be happy to discuss with you about your metabolic disease projects.
Event information: https://t.co/D4mBmi3GgW

[Physiogenex @physiogenex]

We are proud to announce the publication of our collaborative work with the team of Dr. Laurent Martinez (INSERM) on our 3-week NASH mouse model in the @APSPhysiology : https://t.co/GyxOw3WmIT
#NASH #dietarymodel #drugdevelopment

[Physiogenex @physiogenex]

Physiogenex is proud to announce a co-publication with @NovoNordisk in the European Journal of Pharmacology about our db/db mouse model fed a high protein diet: https://t.co/XMCwMcKgDY

To know more about Physiogenex: https://t.co/hlgfE0hiTx

[Physiogenex @physiogenex]

Our co-publication with @Mycrobiota in the @journal_BM, dealing with effects of ultralevure on hypercholesterolemia, is available!

"Saccharomyces boulardii CNCM I-745 changes lipidemic profile and gut microbiota in a hamster hypercholesterolemic model.": https://t.co/Obdfledjbl

[Physiogenex @physiogenex]

Dr. François Briand will be presenting a poster on Monday, June 10, 2019 (12:00 PM - 01:00 PM) at the American Diabetes Association's 79th Scientific Sessions in San Francisco.
Event information: https://t.co/2FxiEStEA8

#ADA2019 #Diabetes

[World Diabetes Day @WDD]

Diabetic retinopathy is a common complication of #diabetes, caused by consistently high levels of blood glucose, together with high blood pressure and high cholesterol. Good management and regular monitoring can reduce the risk https://t.co/8RGmBEUSk4

[Physiogenex @physiogenex]

Today, Dr François Briand attends the 87th EAS Congress at MECC Maastricht Convention Center (Maastricht, Netherlands).

More about the event : https://t.co/h3U6a6jZiq
Visit our Website : https://t.co/55Q4xs6XeL

[Physiogenex @physiogenex]

Physiogenex participera à la course @relais3autaf le 24 mai 2019 avec trois équipes de collaborateurs sur la ligne de départ.

Physiogenex will participate in the @relais3autaf on May 24th, 2019 with three teams on the starting line.

#RSE #Sportsanté

[Physiogenex @physiogenex]

Dr. François Briand will attend the 87th EAS Congress in Maastricht, Netherlands on May 26th 2019. He will be happy to discuss with you about your atherosclerosis projects.
Event information: https://t.co/iWteLjfjJO

[Physiogenex @physiogenex]

Dr Briand attends the 3rd annual edition of #NASH Summit in Boston today!
Meet him to discuss about our innovative #NASH models.

More about the event: https://t.co/fZFiBEJmkK

[Physiogenex @physiogenex]

Physiogenex will attend the 3rd Annual #NASHSummit in Boston on April 23 and 24th, 2019. Our Director of Research and Business Development will present a poster dealing with our innovative #NASH models.

Find more about the event: https://t.co/fZFiBEJmkK

[Physiogenex @physiogenex]

Dr Briand will be at the @Keystone Immunometabolism, Metaflammation and Metabolic Disorders. Join him to learn more about our #NASH models : Fairmont Hotel Vancouver, Vancouver, British Columbia (Pacific Ballroom 7.30 pm).
Find more about the event: https://t.co/8HDOMjUKjz

[Physiogenex @physiogenex]

Dr Briand is now at the @EASLnews annual meeting. Join him at the Messe Wien Exhibition Congress Center to learn more about our #NASH models : Exhibition area Hal B.

More about the event: https://t.co/3QgITt4cAF
Visit our Website: https://t.co/55Q4xsoy6j

[Physiogenex @physiogenex]

Physiogenex will attend the @KeystoneSymp Immunometabolism, Metaflammation and Metabolic Disorders on April 15th, 2019.
Our Director of Research and Business Development will present a poster dealing with our #NASH models.

More about the event: https://t.co/8HDOMjUKjz

[Physiogenex @physiogenex]

Physiogenex will attend the @EASLnews annual meeting on April 12, 2019. Our Director of Research and Business Development will present a poster dealing with our NASH models.

Find more about the event: https://t.co/uSgLbxYT4r

[Physiogenex @physiogenex]

Discover Physiogenex’s 3-week Ultra-fast mouse screening, our in-house model to get quick and complete evaluation for your drug targeting #NASH.
Validated with major benchmarks: elafibranor and liraglutide.
Visit our Website: https://t.co/55Q4xs6XeL
#fattyliver